NYSE: HAEHaemonetics Corp Stock
$70.09-1.27 (-1.78%)
Updated Jun 13, 2025
HAE Price
$70.09
Fair Value Price
N/A
Market Cap
$3.37B
52 Week Low
$55.30
52 Week High
$94.99
P/E
21.05x
P/B
4.1x
P/S
2.34x
PEG
0.93x
Dividend Yield
N/A
Revenue
$1.36B
Earnings
$167.68M
Gross Margin
55%
Operating Margin
16.3%
Profit Margin
12.3%
Debt to Equity
1.99
Operating Cash Flow
$182M
Beta
0.78
Next Earnings
Aug 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
HAE Overview
Haemonetics Corporation provides blood and plasma supplies and services in the U.S. and internationally. Offerings include donor products marketed to the blood donation industry, and products are marketed to the surgical suite for patient blood loss management. The company was founded in 1971 and is headquartered in Boston, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine HAE's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical
Industry Rating
B
HAE
Ranked#20 of 44
Ranked#20 of 44
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $6.21 | A | |
| $9.56 | B | |
| $15.63 | B |
Be the first to know about important HAE news, forecast changes, insider trades & much more!
HAE News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how HAE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HAE ($70.09) is trading above its intrinsic value of $44.94, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
HAE is good value based on its earnings relative to its share price (21.05x), compared to the US market average (31.36x)
P/E vs Market Valuation
HAE is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more HAE due diligence checks available for Premium users.
Valuation
HAE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
21.05x
Industry
38.52x
Market
31.36x
HAE is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
HAE is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
HAE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.1x
Industry
3.59x
HAE is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
HAE price to earnings growth (PEG)
For valuing profitable companies with growth potential
HAE is good value based... subscribe to Premium to read more.
PEG Value Valuation
HAE's financial health
Profit margin
Revenue
$330.6M
Net Income
$58.0M
Profit Margin
17.5%
HAE's Earnings (EBIT) of $221.82M... subscribe to Premium to read more.
Interest Coverage Financials
HAE's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$2.5B
Liabilities
$1.6B
Debt to equity
1.99
HAE's short-term assets ($934.98M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HAE's long-term liabilities ($1.05B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HAE's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
HAE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$116.6M
Investing
$18.0M
Financing
-$151.5M
HAE's operating cash flow ($181.73M)... subscribe to Premium to read more.
Debt Coverage Financials
HAE vs Medical Stocks
Haemonetics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.